title: Gonadotrophins for idiopathic male factor subfertility.
abstract: BACKGROUND
  Male factors leading to subfertility account for at least half of all cases of subfertility worldwide. Although some causes of male subfertility are treatable, treatment of idiopathic male factor subfertility remains empirical. Researchers have used gonadotrophins to improve sperm parameters in idiopathic male factor subfertility with the ultimate goal of increasing birth and pregnancy rates, but results have been conflicting.
  
  
  OBJECTIVE
  To determine the effect of systemic follicle-stimulating hormone (FSH) on live birth and pregnancy rates when administered to men with idiopathic male factor subfertility .
  
  
  METHODS
  We searched the Cochrane Menstrual Disorders and Subfertility Group Specialised Register (14 January 2013), the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library, Issue 12 of 12, 2012), Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE (1946 to 14 January 2013), Ovid EMBASE (1980 to week 2 of 2013), Ovid PsycINFO (1806 to week 2 of 2013), trial registers for ongoing and registered trials at ClinicalTrials.gov (19 January 2013), the World Health Organisation International Trials Registry Platform (19 January 2013), The Cochrane Library Database of Abstracts of Reviews of Effects (19 January 2013) and OpenGrey for grey literature from Europe (19 January 2013). Searches were not limited by language. Bibliographies of included and excluded trials and abstracts of major meetings were searched for additional trials.
  
  
  METHODS
  Randomised controlled trials (RCTs) in which gonadotrophins were compared with placebo or no treatment for participants with idiopathic male factor subfertility.
  
  
  METHODS
  Two review authors independently selected the trials, assessed risk of bias and extracted data on live birth, pregnancy and adverse effects. We included data on pregnancies that occurred during or after gonadotrophin therapy. Study authors and pharmaceutical companies were asked to provide missing and unpublished data and/or additional information.
  
  
  RESULTS
  Six RCTs with 456 participants and variable treatment and follow-up periods were included. From the limited data, the live birth rate per couple randomly assigned (27% vs 0%; Peto odds ratio (OR) 9.31, 95% confidence interval (CI) 1.17 to 73.75, one study, 30 participants, very low-quality evidence) and the spontaneous pregnancy rate per couple randomly assigned (16% vs 7%; Peto OR 4.94, 95% CI 2.13 to 11.44, five studies, 412 participants, I(2) = 0%, moderate-quality evidence) were significantly higher in men receiving gonadotrophin treatment than in men receiving placebo or no treatment. No significant difference between groups was noted when intracytoplasmic sperm injection (ICSI) or intrauterine insemination (IUI) was performed. None of the included studies reported miscarriage rates, and adverse events data were sparse.
  
  
  CONCLUSIONS
  Encouraging preliminary data suggest a beneficial effect on live birth and pregnancy of gonadotrophin treatment for men with idiopathic male factor subfertility, but because the numbers of trials and participants are small, evidence is insufficient to allow final conclusions. Large multi-centre trials with adequate numbers of participants are needed.
authors: Obstetrics & Gynaecology, Faculty of Medicine, Cairo University, 18 El-Ghaith St., Cairo, Egypt, 12311.
authors: Abdelhamid M
authors: AM
authors: Attia
authors: Ahmed M
authors: AM
authors: Abou-Setta
authors: Hesham G
authors: HG
authors: Al-Inany
mesh_terms: D001723:Birth Rate; D005260:Female; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D006062:Gonadotropins / Q000627:therapeutic use; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy*; D008297:Male; D009845:Oligospermia / Q000188:drug therapy; D011247:Pregnancy; D018873:Pregnancy Rate; D016032:Randomized Controlled Trials as Topic
chemical_list: D006062:Gonadotropins; D005640:Follicle Stimulating Hormone
references: J Urol (Paris). 1996;102(2):81-4
references: 8796182
references: Hum Reprod. 1997 Mar;12(3):457-63
references: 9130740
references: Eur J Obstet Gynecol Reprod Biol. 2000 Nov;93(1):105-8
references: 11000513
references: Fertil Steril. 2006 Sep;86(3):728-31
references: 16782097
references: Fertil Steril. 1991 Jun;55(6):1150-6
references: 1903731
references: Fertil Steril. 2002 Feb;77(2):238-44
references: 11821078
references: J Reprod Fertil. 1992 Sep;96(1):91-102
references: 1432977
references: Fertil Steril. 1980 Sep;34(3):269-74
references: 6773823
references: Asian J Androl. 2004 Jun;6(2):133-7
references: 15154088
references: Fertil Steril. 2003 Dec;80(6):1398-403
references: 14667875
references: J Androl. 2003 Jul-Aug;24(4):604-11
references: 12826700
references: Hum Reprod. 1997 Jan;12(1):24-8
references: 9043896
references: Fertil Steril. 1998 Apr;69(4):636-42
references: 9548151
references: Fertil Steril. 1999 Oct;72(4):670-3
references: 10521108
references: Hum Reprod. 1992 Sep;7(8):1067-72
references: 1400928
references: Fertil Steril. 2000 Jan;73(1):24-30
references: 10632407
references: Asian J Androl. 2002 Dec;4(4):281-5
references: 12508129
references: Hum Reprod. 1998 Mar;13(3):596-603
references: 9572419
references: J Clin Endocrinol Metab. 1987 Dec;65(6):1081-7
references: 3119647
references: Fertil Steril. 2005 Sep;84(3):654-61
references: 16169399